sensitivity drugs




sensitive
drug biological extends clinical
therapeutic treatments vary tissue disease variations biological
drug growth breast
tumor breast differentiated mutation status
tissue respond equally drug drug
breast drug
breast researchers clinicians
enable prevent therapeutic working tissue


address



ity lines
copy variants

drugs


comprehensive detailing
mutations



sensitivity anti drugs

copy variations
mutations
effort conduct detailed genomic characterization cancers
publicly aggregated
drugs lines


ccle exists mn
realized early necessitated
careful prevention wanted enable visualization
meaningful


commonly utilized reducing
selecting orthogonal underlying

equivalent
principle

neighbor embedding
neighbor embedding sne
noted maintaining revealing sne calculates
neighborhood utilized
utilized implementations sne
tsne
tsne calculations computationally intensive utilized quad core server gb ram resource consumption
producing fortunately barnes hut sne completed calculations minute

visualizing
visualize
visualization exhibits outcomes gauge
sensitive insensitive lines distinguished plotted
ranked graphs drug
colored sensitivity drug
displayed exhibits strongest
drugs erlotinib typical
unfortunately alone
segregate meaningful










































































































































































































































































erlotinib















































































































































































































































erlotinib


























































































sne





































































































































































































































































































































































































sne












sne










































sne

visualization columns erlotinib
purple sensitive drug insensitive drug
bottom sne
sne



calculations
tsne perplexity controlling
landmarks
methodology examined broad parameterizations tsne
looked parameterizations
visualizes drug


sensitivity divided drug sensitive
sensitive sensitivity held
examined





lm




















raf

pd
azd
tae

zd
azd

pf


erlotinib


pd


aag

plx

nutlin



tsne

tsne

tsne

tsne

tsne

tsne

tsne

tsne



tsne

tsne



tsne

tsne

tsne

tsne

tsne

tsne



tsne



tsne

tsne

tsne

tsne

tsne



tsne

tsne





tsne





tsne

tsne

tsne



tsne



tsne




aag
pd
azd
plx

raf

tae
azd
zd


erlotinib

pf
pd

nutlin




















columns drugs rows parameterization
principle tsne perplexity landmark lighter coloring
rows
sorted bottom worst


analyzed
fnn convenient intuition follow ideal forming bring
geometric


maintaining desire intuitive interpretations examined ccle
hoped hyperplane boundaries formed
nicely



independence assumptions
necessarily hold comparable



nnet
nnet conditional
special scaled




surprisingly drug
drugs confound methodology




























ba




despite implementing seemed reach limit
sensitivity
biologically reality therapeutics designed
dose strongly
assess




experimented implementing lm
simplicity utilized determining



nnet scaled
adjusted


implementations minimal



outperformed

drugs seem inherently easier challenging



aspect interfere interpret
sensitivity designed implies
absolutely growth inhibition transformed closer
sensitive sensitive dealt sophisticated


nutlin


ne


erlotinib
pf


pd


aag
plx









azd
zd
azd
tae
pd

raf
































avg







erlotinib

pf







aag
azd
pd
plx
nutlin


tae
raf
zd
azd

pd



nets



discovered drugs predictable sensitive
sensitive lines plotted begin
separable drugs
follow experimental efforts studying
characterized drugs

conclusions
sensitivity drugs
experimented
attempting
comparable
gauge therapeutics looked closely lines sufficient
address clinical biological
therapeutic efficacy genomics
mutations copy
characterizing particularly
strongly therapeutics biological
biological advances
substantially
interpreting therapeutics
therapeutic cellular therapeutic efficacy biological clinical
toward practical
sensitivity


programming availability
packages sne calculations utilized interface
barnes hut sne

acknowledgements
thank david knowles motivated investigation ccle
processed


